These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 1661057

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM, Laufer DS, Kuter BJ, Staehle B, White CJ, Starr SE.
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH, Saracen CL, Peter G.
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M, Berger R, Just V.
    Dev Biol Stand; 1986 Oct; 65():85-8. PubMed ID: 3030863
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K, Nicoara C, Germann D, Matter L.
    Schweiz Med Wochenschr; 1998 Apr 25; 128(17):649-57. PubMed ID: 9622837
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Reactogenicity and immunogenicity of a live attenuated tetravalent measles-mumps-rubella-varicella (MMRV) vaccine.
    Nolan T, McIntyre P, Roberton D, Descamps D.
    Vaccine; 2002 Dec 13; 21(3-4):281-9. PubMed ID: 12450703
    [Abstract] [Full Text] [Related]

  • 14. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V, Otto W, Maurer L, Tcherepnine P, Pfletschinger U, Kindler K, Soemantri P, Walther U, Macholdt U, Douha M, Pierson P, Willems P.
    Pediatr Infect Dis J; 2008 Aug 13; 27(8):724-30. PubMed ID: 18600190
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA, Svahn A, Rudén U, Bråkenhielm G, Storsaeter J, Akesson L, Linde A.
    Scand J Infect Dis; 2003 Aug 13; 35(10):736-42. PubMed ID: 14606613
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparison of immunogenicity of simultaneous and nonsimultaneous vaccination with MMR and JE vaccine among 15-month-old children.
    Tseng CY, Hwang KP, Lin KH, Chen HY, Lu CC, Chiang CH.
    Acta Paediatr Taiwan; 1999 Aug 13; 40(3):161-5. PubMed ID: 10910607
    [Abstract] [Full Text] [Related]

  • 19. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M, Zepp F, Helm K, Maurer H, Prieler A, Kieninger-Baum D, Douha M, Willems P.
    Eur J Pediatr; 2012 Mar 13; 171(3):463-70. PubMed ID: 21935584
    [Abstract] [Full Text] [Related]

  • 20. Reactogenicity and immunogenicity of a new live attenuated combined measles, mumps and rubella vaccine in healthy children.
    Usonis V, Bakasenas V, Kaufhold A, Chitour K, Clemens R.
    Pediatr Infect Dis J; 1999 Jan 13; 18(1):42-8. PubMed ID: 9951979
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.